48 active not recruiting, 43 recruiting, 37 completed, 26 terminated. 125 Phase 2, 53 Phase 1, 19 Phase 3, 3 Early Phase 1, 2 Not applicable.
Follow IMFINZI: new trials by email Literature Review of IMFINZI trials Research Report on IMFINZI
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-12-10 | 2026-06-10 |
| Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 336 | 2027-01-11 | 2026-08-14 |
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-10-26 |
| A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer | Phase 2 | Recruiting | Jazz Pharmaceuticals | 50 | 2026-11-30 | 2026-09-17 |
| A Multicenter Observational PMS Study Assessing Durvalumab Safety in Indian Adults With Resectable NSCLC IMFINZI - Carcinoma, Non-Small-Cell Lung | Not yet recruiting | AstraZeneca | 78 | 2026-11-30 | 2026-10-30 | |
| Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Ohio State University Comprehensive Cancer Center | 29 | 2026-11-01 | 2026-09-10 |
| Immune-Related Adverse Events and Clinical Outcomes of First-Line Immunotherapy in Egyptian Patients With Unresectable Hepatocellular Carcinoma Atezolizumab plus bevacizumab, Durvalumab Plus Tremelimumab - Hepatocellular Carcinoma, Hepatocellular Carcinoma (HCC) | Not yet recruiting | Assiut University | 294 | 2026-11-01 | 2026-10-29 | |
| A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive Durvalumab, Gemcitabine, Cisplatin - Muscle-Invasive Bladder Cancer (MIBC) | Phase 4 | Not yet recruiting | AstraZeneca | 50 | 2026-10-20 | 2026-10-15 |
| A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma | Phase 2 | Not yet recruiting | Mehmet Akce | 29 | 2026-10-01 | 2026-10-05 |
| Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) Biological: Fecal Microbiota Transplantation, Durvalumab, Paclitaxel - Non Small Cell Lung Cancer, Respiratory Tract Neoplasm | Phase 2 | Not yet recruiting | Fundación GECP | 68 | 2026-09-15 | 2026-05-05 |
| TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma Durvalumab - Esophagogastric Adenocarcinoma | Phase 2 | Not yet recruiting | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | 101 | 2026-07-01 | 2026-04-02 |
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Sacituzumab govitecan, Atezolizumab, Durvalumab - Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC) | Phase 2 | Recruiting | Bindu R Potugari | 35 | 2026-05-14 | 2026-07-28 |
| Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8 | Phase 2 | Recruiting | City of Hope Medical Center | 535 | 2026-05-01 | 2026-10-16 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| Emavusertib (CA-4948) in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer Emavusertib, Gemcitabine, Cisplatin - Metastatic Biliary Tract Cancer, Metastatic Biliary Tract Carcinoma | Phase 1 | Recruiting | Washington University School of Medicine | 48 | 2026-03-27 | 2026-04-03 |
| Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial Atezolizumab, Bevacizumab, Biospecimen Collection - Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 226 | 2026-02-26 | 2026-08-17 |
| A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement Pemigatinib, Durvalumab - Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement | Phase 2 | Recruiting | Mehmet Akce | 38 | 2026-01-27 | 2026-10-05 |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) Rilvegostomig, Durvalumab, Gemcitabine/Cisplatin - Biliary Tract Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-04 | 2026-09-28 |
| Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype | Phase 2 | Recruiting | SWOG Cancer Research Network | 900 | 2025-11-06 | 2026-03-30 |
Showing 20 of 189. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (39) · Lung Neoplasms (30) · Carcinoma, Hepatocellular (17) · Cholangiocarcinoma (12) · Small Cell Lung Carcinoma (11) · Urinary Bladder Neoplasms (11) · Pancreatic Neoplasms (9) · Squamous Cell Carcinoma of Head and Neck (9) · Biliary Tract Neoplasms (8) · Liver Neoplasms (7) · Colorectal Neoplasms (6) · Neoplasm Metastasis (6) · Breast Neoplasms (5) · Triple Negative Breast Neoplasms (5) · Carcinoma, Transitional Cell (4)
National Cancer Institute (NCI) (21) · M.D. Anderson Cancer Center (17) · AstraZeneca (13) · Mayo Clinic (6) · Washington University School of Medicine (6) · University Health Network, Toronto (5) · University of Washington (5) · Jonsson Comprehensive Cancer Center (4) · SWOG Cancer Research Network (4) · Australasian Gastro-Intestinal Trials Group (3) · OHSU Knight Cancer Institute (3) · Stanford University (3) · University of Utah (3) · Canadian Cancer Trials Group (2) · City of Hope Medical Center (2)
United States (134) · Canada (23) · Italy (12) · Germany (11) · Spain (11) · Australia (10) · Netherlands (9) · South Korea (7) · Belgium (6) · China (6) · France (6) · Japan (6) · Poland (6) · Taiwan (6) · United Kingdom (6)
Vassiliki Papadimitrakopoulou (3) · Amir A Jazaeri (2) · Jing Zeng (2) · Lillian Siu, MD (2) · Mariano Provencio, MD (2) · Mehmet Akce, MD (2) · Salah-Eddin Al-Batran, Prof. Dr. (2) · A P Chen (1) · Adel Kardosh (1) · Afshin Dowlati (1) · Alain P Algazi, MD (1) · Albert Chang (1) · Albert J Chang (1) · Alberto A Chiappori, MD (1)
PMID 32379297, PMID 10673991, PMID 16773629, PMID 17997439, PMID 19097774, PMID 21555688, PMID 23770567, PMID 24209604, PMID 24472710, PMID 24476821, PMID 25428503, PMID 26410619, PMID 26487582, PMID 26541610, PMID 27140411, PMID 27262113, PMID 27269937, PMID 27324051, PMID 27345655, PMID 27726966, PMID 28078238, PMID 28259287, PMID 28271869, PMID 28337197, PMID 28481359, PMID 28817753, PMID 28885881, PMID 30406032, PMID 32027845, PMID 32269052, PMID 32379280, PMID 32615102, PMID 33046869, PMID 33125909, PMID 33358660, PMID 33714009, PMID 34006499, PMID 34389237, PMID 34429332, PMID 34499875, PMID 34515338, PMID 34663638, PMID 35033226, PMID 35073853, PMID 36007218, PMID 36125263, PMID 36600534, PMID 36889516, PMID 36912078, PMID 37476372
U10CA180868 (7), U10CA180888 (6), U10CA180820 (5), 2018 (4), 2023 (4), 2025 (2), P30CA015704 (2), P30CA016672 (2), P30CA033572 (2), P30CA138292 (2), UM1CA186688 (2), 2014 (1), 2015 (1), P30CA014089 (1), P30CA015083 (1)